EU/US Properties Organoleptics Cosmetics Suppliers Safety Safety in use Safety references References Other Blenders Uses Occurrence Synonyms Articles Notes
 

laevo-ornithine laevo-aspartate
L-aspartic acid compd. with L-ornithine (1:1)

Supplier Sponsors

CAS Number: 3230-94-2Picture of molecule3D/inchi
ECHA EINECS - REACH Pre-Reg:221-772-7
FDA UNII: JA08T3B97O
MDL:MFCD00058084
Molecular Weight:265.26663000
Formula:C9 H19 N3 O6
NMR Predictor:Predict (works with chrome, Edge or firefox)
Category:information only not used for fragrances or flavors
 
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Google Scholar:Search
Google Books:Search
Google Scholar: with word "volatile"Search
Google Scholar: with word "flavor"Search
Google Scholar: with word "odor"Search
Google Patents:Search
US Patents:Search
EU Patents:Search
Pubchem Patents:Search
PubMed:Search
NCBI:Search
 
Physical Properties:
Appearance:white powder (est)
Assay: 95.00 to 100.00
Food Chemicals Codex Listed: No
Boiling Point: 308.00 to 310.00 °C. @ 760.00 mm Hg
Vapor Pressure:0.000150 mmHg @ 25.00 °C. (est)
Flash Point: 284.00 °F. TCC ( 140.00 °C. )
logP (o/w): -0.963 (est)
Shelf Life: 6.00 month(s) or longer if stored properly.
Storage:refrigerate in tightly sealed containers.
Soluble in:
 water, 1e+006 mg/L @ 25 °C (est)
 
Organoleptic Properties:
Odor Description:bland
Odor and/or flavor descriptions from others (if found).
 
Cosmetic Information:
None found
 
Suppliers:
AuNutra® Industries
L-Ornithine L-Aspartate
BOC Sciences
For experimental / research use only.
L-Ornithine L-aspartate salt
Glentham Life Sciences
L-Ornithine-L-aspartate
Matrix Scientific
For experimental / research use only.
L-Ornithine-L-aspartate, 95+%
sds
Sigma-Aldrich: Sigma
For experimental / research use only.
L-Ornithine L-aspartate salt powder
sds
TCI AMERICA
For experimental / research use only.
L-Ornithine L-Aspartate >96.0%(GC)(T)
sds
 
Safety Information:
Preferred SDS: View
European information :
Most important hazard(s):
None - None found.
S 02 - Keep out of the reach of children.
S 24/25 - Avoid contact with skin and eyes.
 
Hazards identification
 
Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
None found.
GHS Label elements, including precautionary statements
 
Pictogram
 
Hazard statement(s)
None found.
Precautionary statement(s)
None found.
Oral/Parenteral Toxicity:
intraperitoneal-mouse LD50 > 5000 mg/kg
Drugs in Japan Vol. 6, Pg. 164, 1982.

intravenous-mouse LD50 2000 mg/kg
Drugs in Japan Vol. 6, Pg. 164, 1982.

oral-mouse LD50 5000 mg/kg
Drugs in Japan Vol. 6, Pg. 164, 1982.

Dermal Toxicity:
subcutaneous-mouse LD50 > 5000 mg/kg
Drugs in Japan Vol. 6, Pg. 164, 1982.

Inhalation Toxicity:
Not determined
 
Safety in Use Information:
Category:
information only not used for fragrances or flavors
Recommendation for laevo-ornithine laevo-aspartate usage levels up to:
 not for fragrance use.
 
Recommendation for laevo-ornithine laevo-aspartate flavor usage levels up to:
 not for flavor use.
 
Safety References:
EPI System: View
ClinicalTrials.gov:search
AIDS Citations:Search
Cancer Citations:Search
Toxicology Citations:Search
EPA Substance Registry Services (TSCA):3230-94-2
EPA ACToR:Toxicology Data
EPA Substance Registry Services (SRS):Registry
Laboratory Chemical Safety Summary :18599
National Institute of Allergy and Infectious Diseases:Data
WGK Germany:2
(2S)-2-amino-4-hydroxy-4-oxobutanoate; [(4S)-4-amino-5-hydroxy-5-oxopentyl]azanium
Chemidplus:0003230942
RTECS:CI9463000 for cas# 3230-94-2
 
References:
 (2S)-2-amino-4-hydroxy-4-oxobutanoate; [(4S)-4-amino-5-hydroxy-5-oxopentyl]azanium
NIST Chemistry WebBook:Search Inchi
Canada Domestic Sub. List:3230-94-2
Pubchem (cid):18599
Pubchem (sid):134982311
 
Other Information:
(IUPAC):Atomic Weights of the Elements 2011 (pdf)
Videos:The Periodic Table of Videos
tgsc:Atomic Weights use for this web site
(IUPAC):Periodic Table of the Elements
HMDB (The Human Metabolome Database):Search
Export Tariff Code:2922.49.4050
ChemSpider:View
 
Potential Blenders and core components note
None Found
 
Potential Uses:
None Found
 
Occurrence (nature, food, other):note
 not found in nature
 
Synonyms:
(2S)-2-amino-4-hydroxy-4-oxobutanoate; [(4S)-4-amino-5-hydroxy-5-oxopentyl]azanium
L-aspartic acid compd. with L-ornithine (1:1)
laevo-aspartic acid compd. with laevo-ornithine (1:1)
 ornithine aspartate
L-ornithine L-aspartate
 ornithyl aspartate
 

Articles:

PubMed:[The use of remaxol in combined intensive therapy of acute mushroom poisoning].
PubMed:[Meta-analysis of the efficacy and safety of telaprevir combined with peginterferon alfa plus ribavirin in patients with chronic hepatitis C].
PubMed:[Ornithine aspartate and naloxone combined therapy for hepatic encephalopathy affects cognitive function, prognosis, and neuropeptide levels].
PubMed:[Hepatic dysfunction correction in patients with obturation jaundice].
PubMed:Modulation of neural activation following treatment of hepatic encephalopathy.
PubMed:l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.
PubMed:Sequence position and side chain length dependence of charge pair interactions in collagen triple helices.
PubMed:[Hepatic encephalopathy and liver transplantation].
PubMed:Critical analysis of studies evaluating the efficacy of infusion of L-ornithine L-aspartate in clinical hepatic encephalopathy in patients with liver failure.
PubMed:Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
PubMed:[Optimization of treatment of patients with chronic cardiac insufficiency of the ischemic genesis and hobnail liver].
PubMed:Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy.
PubMed:A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.
PubMed:The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition.
PubMed:Hepatic encephalopathy.
PubMed:[Study on L-Ornithine-L-Aspartate in the treatment of acute-on-chronic liver failure].
PubMed:Oral L-ornithine-L-aspartate improves health-related quality of life in cirrhotic patients with hepatic encephalopathy: an open-label, prospective, multicentre observational study.
PubMed:Effect of l-ornithine l-aspartate against thioacetamide-induced hepatic damage in rats.
PubMed:Normal protein diet and L-ornithine-L-aspartate for hepatic encephalopathy.
PubMed:Interorgan ammonia metabolism in liver failure: the basis of current and future therapies.
PubMed:[Physiological functions of L-ornithine and L-aspartate in the body and the efficacy of administration of L-ornithine-L-aspartate in conditions of relative deficiency].
PubMed:[Reduction of hospital stay with the use of L-ornithine L-aspartate (LOLA) in patients with hepatic encephalopathy].
PubMed:[Hepatic encephalopathy. L-ornithine-L-aspartate stimulate detoxification capacity of the liver].
PubMed:Pharmacotherapy for hepatic encephalopathy.
PubMed:A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.
PubMed:Metal toxicity, liver disease and neurodegeneration.
PubMed:Minimal hepatic encephalopathy.
PubMed:A critical analysis of studies assessing L-ornithine-L-aspartate (LOLA) in hepatic encephalopathy treatment.
PubMed:Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study.
PubMed:Treatment of hyperammonemia in liver failure: a tale of two enzymes.
PubMed:L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy.
PubMed:L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis.
PubMed:[Efficiency of prevention and treatment of veno-occlusive disease of the liver after allogeneic stem cell transplantation].
PubMed:[New approach to diagnostics and correction of portohepatic hemodynamics in patients with chronic liver diseases].
PubMed:[Fulminate liver failure in a 39-year-old female patient with leukocytosis, unclear fever, and arthralgic pain].
PubMed:Hepatic encephalopathy: pathophysiology and advances in therapy.
PubMed:The treatment of hepatic encephalopathy.
PubMed:Hepatic encephalopathy following transjugular intrahepatic portosystemic shunt (TIPS): management with L-ornithine-L-aspartate and stent reduction.
PubMed:Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study.
PubMed:Hepatic encephalopathy: a review of its pathophysiology and treatment.
PubMed:Effect of ascorbic acid, alpha-tocopherol, lecithin and L-ornithine-L-aspartate on ethanol induced hypoproteinemia and hyperlipidemia in rats.
PubMed:Pharmacokinetics and bioavailability study of L-ornithine-L-aspartate in healthy volunteers--a comparative study of two oral formulations.
PubMed:Validated method for L-ornithine-L-aspartate analysis in human plasma by capillary electrophoresis.
PubMed:[Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy].
PubMed:Recovery from parkinson syndrome and prolonged visually evoked potentials in hepatic encephalopathy.
PubMed:[Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS)].
PubMed:[New concepts in the physiopathology of hepatic encephalopathy and therapeutic prospects].
PubMed:[Cirrhotic liver gives up in breaking up of ammonia. Poison for the brain].
PubMed:Brain edema in acute liver failure.
PubMed:[Because hepatic encephalopathy is a frequent contributing factor. Patients with liver cirrhosis are poorer drivers].
PubMed:[Hepatic encephalopathy--therapy].
PubMed:Hepatic encephalopathy: nomenclature, pathogenesis and treatment.
PubMed:Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy.
PubMed:Liver transplantation improves hepatic myelopathy: evidence by three cases.
PubMed:Management of hepatic encephalopathy.
PubMed:[Researching progress of prevention and treatment of hepatic failure encephalopathy].
PubMed:[The response to combined therapy of hepatic encephalopathy in patients with hepatic cirrhosis].
PubMed:Proton MR spectroscopy of neurometabolites in hepatic encephalopathy during L-ornithine-L-aspartate treatment--results of a pilot study.
PubMed:[Chronic liver diseases. The nihilism has gone].
PubMed:[In liver cirrhosis, not every "ammonia lowering drug" improves neuropsychiatric deficit].
PubMed:Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial.
PubMed:[Chronic liver diseases. Hepatic encephalopathy too frequently overlooked?].
PubMed:Complications of cirrhosis III. Hepatic encephalopathy.
PubMed:L-ornithine aspartate - a rationale for its use in combination with chemotherapy, radiation, and hyperthermia in oncology.
PubMed:L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure.
PubMed:L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action.
PubMed:Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.
PubMed:Treatment of cirrhotic rats with L-ornithine-L-aspartate enhances urea synthesis and lowers serum ammonia levels.
PubMed:Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
PubMed:L-ornithine vs. L-ornithine-L-aspartate as a treatment for hyperammonemia-induced encephalopathy in rats.
PubMed:Review article: pathogenesis and treatment of chronic hepatic encephalopathy.
PubMed:Contrasting effects of thioacetamide-induced liver damage on the brain uptake indices of ornithine, arginine and lysine: modulation by treatment with ornithine aspartate.
PubMed:[Hepatic minimal encephalopathy. The most frequently overlooked, clinically occult "metabolic syndrome" on the cirrhosis patient].
PubMed:[The treatment of hepatic encephalopathy with Hepa-Mertz].
PubMed:[Ornithine aspartate in hepatic encephalopathy: an established new therapeutic approach. Overview and results of current randomized studies].
PubMed:Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design.
PubMed:Long-term effectiveness of high-dosed ornithine-aspartate on urea synthesis rate and portal hypertension in human liver cirrhosis.
PubMed:[Amino acids prevent hepatic encephalopathy. Ornithine-aspartate in hyperammonemia--results of a study].
PubMed:X-ray studies on crystalline complexes involving amino acids and peptides. IX. Crystal structure of L-ornithine L-aspartate hemihydrate.
PubMed:[Influence of ornithine aspartate on the experimentally induced hyperammoniemia. Clinico-experimental study].
PubMed:Intravenous loading with arginine-hydrochloride and ornithine-aspartate in siblings of two families, presenting a familial neurological syndrome associated with cystinuria.
PubMed:[Clinical experiences in liver diseases (specially in patients with fatty liver due to alcoholism and food poisoning) under monotherapy with ornithine aspartate].
PubMed:[Influence of ornithine-aspartate on the increased GOT activity in bovine serum].
PubMed:[Further clinical experiences with ornithine aspartate in liver diseases].
PubMed:[Effect of ornithine-aspartate on fecal excretion of mevalonate metabolites and the reticuloendothelial system].
PubMed:[Our clinical experience with ornithine aspartate].
PubMed:Protection by ornithine-aspartate of the effects of physical exercise.
PubMed:[Radiophysical studies: irradiation of ornithine aspartate in the Siemens training reactor SUR 100].
PubMed:[Personal experiences in the treatment of internal diseases with ornithine aspartate].
PubMed:[Experiences with ornithine-aspartate in liver diseases].
PubMed:[On the therapy of liver diseases with ornithine aspartate].
PubMed:[Intravenous administration of ornithine aspartate to patients with hepatic diseases].
PubMed:Effect of ornithine-aspartate mixture on 15N-ammonia incorporation into urea in intact mice.
PubMed:[Study of the treatment of liver damage due to several causes in tuberculosis, using ornithine-aspartate].
 
Notes:
used therapeutically in hepatic coma.
Please share your Comments.
Email Address:
Top of Page Home
Copyright © 1980-2021 The Good Scents Company (tgsc) ™ Disclaimer Privacy Policy